Global Retropharyngeal abscess Market Size, Share, Forecast Report, 2020-2027

A retropharyngeal abscess is a serious infection, usually starts in the lymph nodes, characterised by collection of pus at the back of the throat. Retropharyngeal abscess typically occurs in children under the age of eight, sometimes it can also affect adults. The symptoms of retropharyngeal abscess include difficulty or noisy breathing, difficulty and pain while swallowing, drooling, severe cough, severe throat pain, neck stiffness or swelling, muscle spasms in the neck among others. Retropharyngeal abscess is generally preceded by upper respiratory infections mostly a middle ear or sinus infection.

The causes of retropharyngeal abscess are trauma or injury, medical procedure, dental procedures, alcohol intake, diabetes, cancer, AIDS, weakened immune system or a chronic diseases such as tuberculosis and others. Other complications indicated are pneumonia, blood clots in the jugular vein, mediastinitis, osteomyelitis and others. If left untreated, retropharyngeal abscess infection can spread to other parts of the body resulting in septic shock and organ failure. In severe instances, a retropharyngeal abscess can lead to death. The most common bacteria involved are Streptococcus, Staphylococcus, and others. Other infections, such as HIV and tuberculosis can also cause the retropharyngeal abscess. Retropharyngeal abscess recurs in an estimated 1 to 5% of patients and such patients are 40 to 50% more likely to die due to abscess-related complications. Retropharyngeal abscess also slightly more common in males than females.

The market drivers for global retropharyngeal abscess market, are rise in demand due to the growing younger and susceptible population, increasing screening, urgency of the retropharyngeal abscess treatment, and rise in risk factors. The rise in cases of retropharyngeal abscess due to increase in Methicillin-resistant Staphylococcus aureus (MRSA) infections also stimulates the market. The market restraints are complications such as risk of bleeding, infections, pain, especially during surgery, high cost of retropharyngeal abscess treatment, lack of cardiac care infrastructure, and lack of focus on other diseases by the developing regions and others.

The global retropharyngeal abscess market is expected to reach USD 5.9 billion by 2023, and the market is projected to grow at a CAGR of ~ 4.5 % during the forecast period 2017-2023.
Segments
The global retropharyngeal abscess market has been segmented on the basis of diagnosis, treatment, and end user.

Based on the diagnosis, the market has been segmented as X-rays and computed tomography, blood tests, physical exam and others.

Based on the treatment, the market has been segmented as calcium antibiotics, pain killers, surgical drainage and others.

Based on the end user, the market has been segmented as hospitals and clinics, research and academics and others.
Key Players in the Global Retropharyngeal abscess Market
Some of the key players profiled in the report are Merck KGaA, Johnson & Johnson, AstraZeneca plc, Sanofi S.A., Pfizer, Mylan N.V, Novartis AG, Teva pharmaceutical company, GlaxoSmithKline plc., and others.